Skip to main content
SpringerLink
Log in

GCKR polymorphism influences liver fat content in patients with type 2 diabetes

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Aims

It has recently been shown that an allele in the glucokinase regulatory protein (GCKR) gene was associated with increased liver fat content in obese children. In this study, we set out to determine whether GCKR rs1260326 polymorphism was associated with liver fat content in patients with type 2 diabetes.

Methods

Three hundred and eight patients with type 2 diabetes were included in this study. Liver fat content was evaluated using 1H-MR spectroscopy.

Results

In our population, carriers of the rs1260326 minor T allele had a higher liver fat content than did carriers of the C allele homozygote (12.4 ± 9.6 vs. 10.3 ± 9.1 %, p = 0.03). The number of patients with steatosis was significantly higher in minor T allele carriers than in C allele homozygote carriers (70.7 vs. 55.4 %; p = 0.008). In multivariate analysis, the predictive variables for steatosis were BMI [odds ratio (OR) 1.08; 95 % confidence interval (CI) 1.03–1.13; p = 0.002], statin therapy (yes) [OR 0.54; 95 % CI 0.31–0.94; p = 0.03], metformin therapy (yes) [OR 2.67; 95 % CI 1.50–4.75; p < 0.001], and rs1260326 GCKR polymorphism (TT+CT) [OR 1.99; 95 % CI 1.14–3.47; p = 0.01].

Conclusions

This study shows that in patients with type 2 diabetes who were not selected for liver abnormalities, liver fat content was related to GCKR rs1260326 polymorphism independent of BMI, triglyceride levels, and age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

GCKR:

Glucokinase regulatory protein

NAFLD:

Non-alcoholic fatty liver disease

LFC:

Liver fat content

References

  1. Cusi K (2009) Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16:141–149

    Article  PubMed  Google Scholar 

  2. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218

    Article  PubMed  Google Scholar 

  3. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R et al (2008) Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31:165–169

    Article  CAS  PubMed  Google Scholar 

  4. Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V et al (2009) Non-alcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 94:4103–4106

    Article  CAS  PubMed  Google Scholar 

  5. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P et al (2010) Specifically-PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 95:E430–E436

    Article  CAS  PubMed  Google Scholar 

  7. Speliotes EK, Yerges-Armstrong L, Wu J, Hernaez R, Kim L, Palmer C, Gudnason V et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R et al (2012) Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55:781–789

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Petta S, Miele L, Bugianesi E, Cammà C, Rosso C, Boccia S et al (2014) Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 9:e87523

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rees MG, Wincovitch S, Schultz J, Waterstradt R, Beer NL, Baltrusch S et al (2012) Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55:114–122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Guiu B, Petit JM, Loffroy R, Ben Salem D, Aho S, Masson D et al (2009) Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 250:95–102

    Article  PubMed  Google Scholar 

  13. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387–1395

    Article  PubMed  Google Scholar 

  14. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S et al (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462–E468

    Article  CAS  PubMed  Google Scholar 

  15. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T et al (2010) Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105:1567–1573

    Article  PubMed  PubMed Central  Google Scholar 

  16. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M (1999) Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22:756–761

    Article  PubMed  Google Scholar 

  17. Lynedjian PB (2009) Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 66:27–42

    Article  Google Scholar 

  18. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M et al (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18:4081–4088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sparsø T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70–75

    Article  PubMed  Google Scholar 

  20. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Königsrainer A et al (2011) Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96:E1126–E1130

    Article  PubMed  Google Scholar 

  22. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC et al (2011) Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34:1139–1144

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the Centre Hospitalier Universitaire de Dijon and the Conseil Régional de Bourgogne (AOI 2010). We thank Dr C Bonithon-Kopp of the Centre d’Investigation Clinique–INSERM CHU de Dijon for assistance with this study Sabrina Cousin and Francoise Virely for technical assistance and Philip BASTABLE for his help in reviewing the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical disclosure

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Author information

Authors and Affiliations

  1. Centre de Recherche INSERM Unité 866, Université de Bourgogne, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France

    Jean-Michel Petit, David Masson, Boris Guiu, Fabien Rollot, Laurence Duvillard, Benjamin Bouillet, Marie-Claude Brindisi, Patrick Hillon & Bruno Verges

  2. Services de diabétologie et endocrinologie, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France

    Jean-Michel Petit, Benjamin Bouillet, Marie-Claude Brindisi, Perrine Buffier & Bruno Verges

  3. de radiologie, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France

    Boris Guiu & Jean-Pierre Cercueil

  4. d’hépatologie, CHU du Bocage, BP 77908, 21079, Dijon Cedex, France

    Patrick Hillon

Authors
  1. Jean-Michel Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Masson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boris Guiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fabien Rollot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laurence Duvillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Benjamin Bouillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marie-Claude Brindisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Perrine Buffier
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patrick Hillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jean-Pierre Cercueil
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Bruno Verges
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Michel Petit.

Additional information

Managed by Massimo Federici.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petit, JM., Masson, D., Guiu, B. et al. GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetol 53, 237–242 (2016). https://doi.org/10.1007/s00592-015-0766-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-015-0766-4

Keywords

Search

Navigation